Gilead (GILD): analysis in plain words
Is Gilead cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Gilead (GILD) is listed on the Nasdaq and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Gilead according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Gilead (GILD) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $174.48 | Last price on November 4, 2026 |
| P/E ratio (TTM) | N/A | Price over earnings per share |
| Revenue growth | +6.8% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | -12.5% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.2x | Years of operating profit to repay debt |
| Dividend yield | 1.96% | Annual dividend over price |
| Market cap | $216.4 billion | What the stock market values it at |
The Gilead figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any GILD figure that is not available shows as N/A: we do not estimate it.
How Gilead makes money
Gilead Sciences is a biotech whose largest revenue source is HIV treatment and prevention, led by Biktarvy, alongside Descovy and Yeztugo. It also sells cancer drugs, including Trodelvy and Kite's cell therapies Yescarta and Tecartus, liver disease treatments such as Epclusa and Livdelzi, and the antiviral Veklury.
Over the last 12 months, Gilead brought in revenue of $31.0 billion. For every 100 it sells, Gilead keeps 79.9 after the direct cost of what it sells (gross margin) and 42.4 after all operating costs (operating margin). With 17,000 full-time employees, that is about $2 million of revenue per employee.
Gilead against its sector
To know whether a Gilead figure is high or low you have to put it next to similar companies. This table compares Gilead with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Gilead | healthcare and pharma median |
|---|---|---|
| Revenue growth | +6.8% | +8.3% (33) |
| Net margin | -12.5% | 14.9% (33) |
| Dividend yield | 1.96% | 1.52% (33) |
| Net debt / EBITDA | 1.2x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Gilead grows more slowly, earns a thinner margin and pays a higher dividend yield. By size, Gilead ranks number 8 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Gilead
What works in favour of Gilead, according to its figures as of November 4, 2026:
- Gilead generates real cash: $10.7 billion of free cash flow over 12 months, 4.9% of its stock market value.
The main risk for Gilead
Gilead is losing money: its net margin over the last 12 months is -12.5%, so it spends more than it brings in. Until it turns a profit it relies on its cash or on raising money.
And, like the rest of healthcare and pharma, Gilead is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Gilead
Is it a good time to buy Gilead stock?
Fintols does not tell you whether to buy or sell Gilead, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Gilead stock trades at $174.48, 1% below its 52-week high ($175.65) and 49% above its low ($116.88). With Gilead, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Gilead pay a dividend?
Yes. As of November 4, 2026, Gilead pays $3.28 per share a year, which at today's price is a yield of 1.96%. It uses 43% of its profit to pay it, which leaves room to keep paying it if profit dips. Its average dividend yield over the last five years is 3.29%. The healthcare and pharma median on Fintols is 1.52%.
Is Gilead stock expensive?
Gilead has no meaningful P/E as of November 4, 2026 because its last 12 months of earnings are negative or close to zero, so that yardstick cannot tell you whether it is expensive. Including its debt, Gilead is valued at 15.4x its EBITDA (EV/EBITDA). A high P/E alone does not make Gilead expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Gilead's competitors?
On Fintols we compare Gilead with Bristol Myers Squibb, CVS Health and Danaher, which are also in healthcare and pharma. As of November 4, 2026, Bristol Myers Squibb is worth $131.2 billion and trades on a P/E of 14.2; CVS Health is worth $102.3 billion and trades on a P/E of 21.0; Danaher is worth $165.2 billion and trades on a P/E of 38.9. Each has a side-by-side comparison with Gilead below.
Gilead competitors
- Bristol Myers Squibb (BMY) analysis · Gilead vs Bristol Myers Squibb comparison
- CVS Health (CVS) analysis · Gilead vs CVS Health comparison
- Danaher (DHR) analysis · Gilead vs Danaher comparison
To understand Gilead better
- DCF and WACC Explained: A Practical Valuation Guide
- 7 Common Beginner Investing Mistakes (and How to Avoid Them)
More companies like Gilead: healthcare and pharma stocks, S&P 500 companies and S&P 100 companies. Open the full GILD analysis with its valuation and scenarios. Educational content about Gilead, not investment advice.